Skip to main content

Palboxen 125 mg (Palbociclib)

Introduction to Palbociclib

Palbociclib is an oral targeted anticancer medicine classified as a selective cyclin-dependent kinase 4 and 6 inhibitor.

It is used in specified breast cancer treatment settings, particularly HR-positive, HER2-negative advanced or metastatic disease, in combination with endocrine therapy.

The clinical rationale for palbociclib is based on the role of CDK4 and CDK6 in regulating the cell cycle. These proteins help control the transition from the G1 phase to the S phase, allowing cells to prepare for DNA replication and division.

In certain cancer cells, signaling through cyclin D and CDK4/6 contributes to abnormal cell proliferation. Inhibiting this pathway can interrupt cell-cycle progression.

Palbociclib is not a general anticancer treatment for every tumor type. Its clinical use is determined by the disease characteristics, approved treatment setting and patient’s overall clinical condition.

Pharmacological Classification

CharacteristicInformation
Generic namePalbociclib
Drug classCDK4/6 inhibitor
Therapeutic categoryAntineoplastic medicine
Pharmacological actionInhibition of CDK4 and CDK6
Main treatment areaSelected breast cancer settings
Principal receptor profileHR-positive, HER2-negative
Route for reference productsOral
Common reference starting dose125 mg once daily
Common reference schedule21 days on treatment followed by 7 days off

The listed starting dose and schedule describe a commonly used reference regimen. They are not an individualized recommendation and do not establish the exact instructions for every Palboxen presentation.

Mechanism of Action

The cell cycle is the process through which cells grow and divide. It is controlled by a network of proteins that regulate when a cell can progress from one phase to another.

CDK4 and CDK6 are important regulators of the transition from the G1 phase to the S phase.

In normal cellular regulation, cyclin D binds to CDK4 and CDK6. The resulting complexes can phosphorylate the retinoblastoma protein, also known as Rb.

When Rb is phosphorylated, it releases regulatory proteins that allow the cell to progress toward DNA replication.

In certain breast cancer cells, this pathway becomes overactive and contributes to uncontrolled cell growth.

Palbociclib inhibits CDK4 and CDK6. This reduces Rb phosphorylation and can prevent susceptible cancer cells from progressing from G1 into S phase.

The resulting effect is cell-cycle arrest.

This mechanism provides the pharmacological basis for combining palbociclib with endocrine therapy in selected HR-positive breast cancer settings.

Clinical Role in Breast Cancer

Palbociclib is used in specified treatment combinations for advanced or metastatic breast cancer.

Its established clinical role includes hormone receptor-positive and HER2-negative disease.

Hormone receptor-positive breast cancer is characterized by the presence of estrogen receptors, progesterone receptors or both. These receptors can contribute to cancer-cell growth through hormone signaling.

HER2 status is another important factor in breast cancer classification. HER2-negative disease does not meet the criteria for HER2-positive disease based on appropriate testing.

The combination of palbociclib and endocrine therapy targets complementary biological pathways.

Endocrine therapy reduces hormone-related signaling, while palbociclib inhibits CDK4/6-mediated cell-cycle progression.

The selection of a treatment regimen depends on the patient’s disease characteristics, previous treatment, menopausal status and applicable prescribing guidance.

Combination Treatment

Palbociclib is generally used in combination with endocrine therapy rather than as an isolated treatment for its principal established breast cancer indications.

Treatment partners may include:

Aromatase inhibitors: These medicines reduce estrogen production. They may be used in appropriate hormone receptor-positive breast cancer settings.

Fulvestrant: This medicine acts on estrogen receptors and may be used in specified treatment settings.

Ovarian suppression: In premenopausal or perimenopausal women, a GnRH agonist may be required alongside endocrine treatment to suppress ovarian function.

The appropriate combination is determined by the treating oncologist.

Not every combination is appropriate for every patient, and regulatory indications may differ between countries.

Dosage and Treatment Schedule

A commonly used reference palbociclib regimen begins at 125 mg once daily for 21 consecutive days, followed by 7 days without palbociclib.

This is known as a 28-day treatment cycle.

Cycle periodTreatment
Days 1–7Prescribed daily dose
Days 8–14Prescribed daily dose
Days 15–21Prescribed daily dose
Days 22–28Treatment break

A new cycle may begin after the break when the oncology team determines that treatment can safely continue.

Dose modifications may be necessary for neutropenia and other adverse reactions. Common reference dose levels include 125 mg, 100 mg and 75 mg.

The specific dose must be determined by the treating specialist.

Pharmacokinetic Considerations

Pharmacokinetics describes how a medicine is absorbed, distributed, metabolized and eliminated by the body.

Palbociclib is administered orally in its reference formulations and undergoes metabolism involving the CYP3A enzyme system.

This is clinically important because medicines that inhibit or induce CYP3A can affect palbociclib exposure.

Strong CYP3A inhibitors can increase palbociclib concentrations and may increase the risk of adverse reactions. Strong CYP3A inducers can reduce palbociclib exposure and may compromise treatment effectiveness.

The oncology team should review all medicines, supplements and herbal preparations before and during treatment.

Patients should not independently discontinue another medicine or alter their palbociclib dose to manage a possible interaction.

Clinical Monitoring

Monitoring is an essential part of palbociclib treatment.

The most important routine laboratory assessment is the complete blood count.

Palbociclib can reduce neutrophil counts and affect other blood-cell lines. Blood-count monitoring helps identify these changes and determine whether treatment can continue safely.

Monitoring commonly includes:

Monitoring areaClinical purpose
Complete blood countIdentify neutropenia, anemia and thrombocytopenia
Neutrophil countAssess infection risk and treatment tolerance
Platelet countIdentify thrombocytopenia
HemoglobinAssess anemia
Liver functionEvaluate possible hepatic abnormalities
Clinical assessmentReview symptoms and adverse reactions
Medication reviewIdentify possible drug interactions
Respiratory symptomsAssess possible pneumonitis or interstitial lung disease

The frequency of testing should follow the applicable prescribing information and the patient’s clinical condition.

Neutropenia and Infection Risk

Neutropenia is one of the most important adverse effects associated with palbociclib.

Neutrophils are white blood cells that help the immune system fight infections. A reduction in their number can increase susceptibility to bacterial and fungal infections.

A patient with neutropenia may not always experience obvious symptoms before an infection develops.

Symptoms that require prompt medical assessment include:

  • Fever.
  • Chills.
  • Persistent cough.
  • Sore throat.
  • Painful urination.
  • New skin redness or swelling.
  • Unexplained weakness.
  • Other signs of infection.

Patients should follow the specific fever-management instructions provided by their oncology team.

Dose Interruption and Reduction

Palbociclib treatment may need to be interrupted or reduced when clinically significant adverse reactions occur.

Neutropenia is a frequent reason for dose modification.

The treating specialist considers the severity and duration of the blood-count changes, the presence of infection, other adverse effects and the patient’s overall condition.

Common reference dose levels include:

  • 125 mg once daily.
  • 100 mg once daily.
  • 75 mg once daily.

Further treatment decisions depend on the applicable product labeling and the nature of the adverse reaction.

Patients should not independently restart treatment after an interruption or use a lower dose without medical instructions.

Important Clinical Safety Considerations

Interstitial lung disease and pneumonitis: Rare cases of serious lung inflammation have been reported with palbociclib and other CDK4/6 inhibitors. New or worsening respiratory symptoms should be assessed promptly.

Liver abnormalities: Liver-function changes may occur. Clinical assessment and laboratory monitoring may be necessary.

Drug interactions: Strong CYP3A inhibitors and inducers may significantly affect palbociclib exposure.

Pregnancy: Palbociclib may cause fetal harm. Appropriate pregnancy-prevention advice should be provided by the treating specialist.

Breastfeeding: Breastfeeding precautions should be discussed with the healthcare professional because of potential risks to the infant.

Clinical Evidence and Treatment Expectations

Clinical research has evaluated palbociclib in combination with endocrine therapy in different breast cancer treatment settings.

The evidence supporting its use is based on clinical trials and subsequent regulatory assessments. These studies have examined treatment outcomes such as progression-free survival, response and safety.

Clinical trial results describe outcomes in defined study populations. They cannot predict exactly how an individual patient will respond.

Some patients may experience disease control for a period of time, while others may experience progression or require a change in treatment because of adverse effects or other clinical considerations.

The treatment plan should be reviewed regularly by the oncology team.

Frequently Asked Questions

1. What is the pharmacological class of palbociclib?

Palbociclib is a selective cyclin-dependent kinase 4 and 6 inhibitor.

2. What is the mechanism of action of palbociclib?

It inhibits CDK4 and CDK6, reducing Rb phosphorylation and interfering with progression from the G1 phase to the S phase of the cell cycle.

3. Why is palbociclib combined with endocrine therapy?

The combination targets both hormone-related signaling and cell-cycle regulation in selected hormone receptor-positive breast cancer settings.

4. What is the commonly used starting dose?

A common reference starting dose is 125 mg once daily for 21 days followed by 7 days off. The patient’s prescribed dose may differ.

5. Why is a seven-day break included?

The treatment break is part of the reference 28-day cycle and provides time for recovery from treatment-related effects, including changes in blood-cell counts.

6. Which blood tests are important during treatment?

Complete blood counts are particularly important. Other laboratory tests may be requested depending on the patient’s clinical condition and treatment plan.

7. What is the most important blood-related adverse effect?

Neutropenia is a major safety concern because it can increase the risk of infection.

8. Can palbociclib interact with other medicines?

Yes. Medicines that strongly inhibit or induce CYP3A can affect palbociclib exposure. A healthcare professional should review all medicines and supplements.

9. Can the palbociclib dose be reduced?

Yes. Dose interruptions and reductions are used when necessary to manage certain adverse reactions. The decision belongs to the treating specialist.

10. Is palbociclib appropriate for all breast cancer types?

No. Its use is limited to specific clinical settings and depends on tumor characteristics and applicable treatment guidance.

Clinical Information Disclaimer

This page provides general educational information about palbociclib. It does not replace the official prescribing information or an individualized clinical assessment.

Treatment indications, dosing, monitoring and safety recommendations must be confirmed using the current product information applicable to the patient’s country and formulation.